022 24172311
Sections
Search
DealCurry
Equity
Venture Capital
Private Equity
M&A

Banner
DataBoard Demo
Mergers & Acquisitions | 11 July 2013

Tech Mahindra Plans Overseas Acquisitions

by Tilak Devadiga
Tech Mahindra Plans Overseas Acquisitions
Share on Social Media Email Facebook Twitter Linkedin
 
@tilak

Tech Mahindra is planning for global acquisitions and is more keen on Australia to enhance its capabilities.

Tech Mahindra is looking for acquisitions in BFSI , telecom and healthcare sectors. It is also considering players to enhance its future technology offerings such as NMACS (Networks, mobility, analytics, cloud and security).

Australia which is a major contributor to the company’s revenue from the Rest Of the World (RoW) region is been looked upon as an alternate growth center following the slowdown in major economies like The US and UK. This region contributes 24 % to the combined turnover of $2.7 billion of the company and houses one fourth of its 84000 RoW employees.

The company is aiming to increase its volumes and targeting revenues of $5 Bn by 2015, post the acquisition.

In Japan, China and Korea, it is looking at forging partnerships with local companies. In the east, the company has operations in Vietnam and plans to start in Taiwan. Other target markets include Indonesia, the Philippines, Malaysia.

Tech Mahindra, part of the $16.2 Bn Mahindra Group, is a leading global systems integrator and business transformation consulting organization, focused primarily on the telecommunications industry. Tech Mahindra has a global footprint through operations in more than 31 countries with 17 sales offices and 15 delivery centers.

Major acquisitions by Tech Mahindra include ;

  • Type Approval Lab based in Sweden
  • Bharti Enterprises’ promoted Comviva Technologies
  • BPO player Hutchison Global Services

Jain Irrigation To Exit Its Wind Power Biz

Jain Irrigation To Exit Its Wind Power Biz

Jain Irrigation Systems is planning to divest its wind power business to bring down its debt by R63 Cr. This business is part of non-integral business lines. The transaction when completed shall result in reduction of foreign currency debt of $10.5 Mn from the books of the company.

Read More...

Update: ChrysCapital Exits Pharmaceutical Company Mankind Pharma

Update: ChrysCapital Exits Pharmaceutical Company Mankind Pharma

ChrysCapital has sold its 11% stake in Mankind Pharma to Capital International for over R1276.2 Cr ($200 Mn) which is 10x the value of its original investment, valuing the company at about $2.2 Bn.

Read More...
Subscribe
Enter your Email address
to receive all the news